IGF-1 LR3 (Long R3 Insulin-Like Growth Factor-1 / Recombinant 83-Amino-Acid Polypeptide) is an structural analogue of IGF-1 featuring a Glu3Arg substitution and a 13-amino-acid N-terminal leader extension. This targeted modification reduces binding affinity for inhibitory IGF-Binding Proteins (IGFBPs 1–6) by over 100-fold, creating a stable, high-potency ligand for Type 1 IGF Receptors (IGF-1R). Receptor binding activates intrinsic tyrosine kinase phosphorylation and recruits IRS-1 to stimulate the PI3K/Akt/mTORC1 signaling cascade, accelerating cellular protein synthesis, activating myogenic satellite cells, and suppressing ubiquitin-mediated proteolysis. Modern Aminos supplies analytical-grade IGF-1 LR3 in a 1MG lyophilized dry solid 2R glass vial format strictly for in vitro laboratory research, receptor tyrosine kinase assays, and skeletal muscle bioenergetics screening.
Original price was: $64.00.$44.80Current price is: $44.80.
In stock
| Quantity | Discounted Price |
|---|---|
| 4 - 6 | $61.44 |
| 7 - 9 | $60.16 |
| 10 + | $58.88 |
IGF-1 LR3 (known chemically as Long Arg3 Insulin-Like Growth Factor-1) is an 83-amino-acid recombinant polypeptide analogue of endogenous IGF-1. Engineered to overcome the rapid clearance kinetics and inhibitory sequestration associated with native growth factors, IGF-1 LR3 incorporates two critical structural modifications: the substitution of an arginine for glutamic acid at position 3 (Glu3Arg) and the addition of a 13-amino-acid peptide extension sequence (MFPAMPLSSLFVN) at the N-terminus.
In cellular and tissue explant models, native IGF-1 is rapidly sequestered by high-affinity Insulin-Like Growth Factor-Binding Proteins (IGFBPs 1–6), limiting its biological availability. The structural alterations in IGF-1 LR3 reduce its binding affinity for IGFBPs by over 100- to 1000-fold without compromising its ability to bind and activate the Type 1 IGF Receptor (IGF-1R).
Consequently, IGF-1 LR3 functions as a high-potency, long-acting molecular probe. Receptor ligation triggers IGF-1R autophosphorylation and recruits insulin receptor substrate 1 (IRS-1), stimulating the phosphoinositide 3-kinase (PI3K) / Akt / mechanistic target of rapamycin complex 1 (mTORC1) signaling cascade to drive ribosomal protein synthesis, activate myogenic satellite cells, and downregulate ubiquitin-mediated proteolytic pathways.
Batch-verified for high analytical purity and mass accuracy through the Quality Assurance Program at Modern Aminos, IGF-1 LR3 is offered as a standardized 1MG lyophilized dry solid in a 2R glass vial. Researchers evaluating skeletal muscle differentiation, receptor tyrosine kinase kinetics, and anabolic signaling cascades utilize IGF-1 LR3 as a benchmark reference standard for cellular bioenergetics research.
| Compound Name | IGF-1 LR3 (Long Arg3 Insulin-Like Growth Factor-1) |
|---|---|
| Format / Quantity | 1MG Lyophilized Dry Powder in 2R Glass Vial |
| Biological Target | Type 1 Insulin-Like Growth Factor Receptor (IGF-1R) / Skeletal Muscle Myoblasts |
| Chemical Classification | Recombinant Polypeptide Analogue (83 Amino Acids / 3 Disulfide Bridges) |
| Primary Modifications | N-Terminal 13-Amino-Acid Leader Peptide Extension + Glu3Arg Substitution |
| Synonyms / Alt Names | Long-R3-IGF-1, LR3 IGF-1, Recombinant Long R3 IGF-1 |
| CAS Number | 946870-92-4 | 143045-27-6 |
| Chemical Formula | C400H625N111O115S9 |
| Molecular Weight | 9111.5 Da (9.11 kDa) |
| Primary Signal Transduction | IGF-1R Autophosphorylation → IRS-1 → PI3K / Akt → mTORC1 / p70S6K |
| Physical Appearance | White Lyophilized Solid Cake |
The biochemical pathways and cellular targets of IGF-1 LR3 in laboratory research include:
When evaluating published scientific literature and cellular monographs for IGF-1 LR3:
In skeletal muscle biology, endocrinology, and cellular proliferation research, reference standards operate across distinct tiers of the somatotropic axis—functioning either as direct downstream receptor ligands or upstream pituitary secretagogues:
| Compound / Reference | Chemical Structure & Class | Primary Mechanistic Target | Somatotropic Axis Level & Research Profile |
|---|---|---|---|
| IGF-1 LR3 | 83-Amino-Acid Recombinant Polypeptide | Type 1 IGF Receptor (IGF-1R); evades IGFBPs | Downstream Direct; continuous, long-acting PI3K/Akt/mTOR protein synthesis and satellite cell proliferation |
| IGF-1 DES (1-3) | 67-Amino-Acid Truncated Polypeptide | Type 1 IGF Receptor (IGF-1R); evades IGFBPs | Downstream Direct; rapid-onset, localized, high-intensity receptor activation with short duration of action |
| Hexarelin | Synthetic Hexapeptide GHRP | Pituitary GHSR-1a & Scavenger CD36 Receptors | Upstream Secretagogue; high-potency pituitary GH release via IP3/Ca2+ mobilization and CD36 signaling |
| GHRP-2 (Pralmorelin) | Synthetic Hexapeptide GHRP | Anterior Pituitary GHSR-1a Receptors | Upstream Secretagogue; physiological pulsatile GH release with moderate endocrine selectivity |
| GHRP-6 | Synthetic Hexapeptide GHRP | Pituitary & Hypothalamic GHSR-1a Receptors | Upstream Secretagogue; pulsatile GH stimulation combined with hypothalamic orexigenic receptor activation |
Yes, Modern Aminos is a highly trusted vendor for high-purity research chemicals and reference peptides. Every batch of IGF-1 LR3 1MG undergoes strict third-party analytical testing (including HPLC and Mass Spectrometry) through our dedicated quality assurance protocols to verify minimum 97%+ chemical purity, correct 83-amino-acid sequence fidelity, verified molecular weight (~9111.5 Da), and complete absence of heavy metals or synthesis impurities.
IGF-1 LR3 is an 83-amino-acid recombinant analogue of endogenous IGF-1. It is modified with an arginine substitution at position 3 (Glu3Arg) and an additional 13-amino-acid N-terminal peptide extension (MFPAMPLSSLFVN), creating a 9.11 kDa polypeptide engineered to resist binding-protein sequestration.
The Glu3Arg mutation alters key electrostatic interactions required for IGFBP docking, while the N-terminal extension sterically hinders binding proteins (IGFBPs 1–6). This reduces binding affinity by over 100-fold, allowing the free peptide to continuously engage the Type 1 IGF Receptor.
Modern Aminos supplies analytical-grade IGF-1 LR3 as a 1MG lyophilized dry solid cake in a sterile 2R glass vial, ensuring solid-state polypeptide stability and precise gravimetric mass control for benchtop research assays.
Binding to the IGF-1R tyrosine kinase triggers IRS-1 phosphorylation, activating the PI3K/Akt pathway. Activated Akt stimulates mTORC1 and p70S6K to drive ribosomal protein translation, while inhibiting FoxO transcription factors and proteasomal ubiquitin ligases (MuRF1 and Atrogin-1).
IGF-1 LR3 and IGF-1 DES act directly on peripheral IGF-1R; LR3 provides prolonged systemic signaling, whereas DES provides rapid, transient localized activation. In contrast, Hexarelin and GHRP-2 operate upstream at pituitary GHSR-1a receptors to stimulate endogenous growth hormone release, which secondarily drives hepatic IGF-1 output.
Modern Aminos utilizes High-Performance Liquid Chromatography (HPLC) to confirm active polypeptide purity exceeding 98% and Mass Spectrometry (MS) to verify exact molecular mass (~9111.5 Da) and primary sequence structure prior to batch release.
Lyophilized IGF-1 LR3 glass vials should be stored tightly sealed in a cool, dry environment (15°C to 25°C) or refrigerated (2°C to 8°C) for long-term preservation. Protect from direct light, heat exposure, and atmospheric moisture to maintain solid-state peptide stability.
Disclaimer: All compounds and research materials provided by Modern Aminos are strictly for laboratory and research professional use only. They are not approved for human or animal use nor consumption by the Food and Drug Administration (FDA). These products should not be used for any form of in vivo experimentation or for any other non-laboratory purpose. Any violation or indication of human or animal use will result in immediate removal from being able to purchase products in the future. By purchasing these products, you acknowledge that they will be used exclusively within a controlled and qualified research environment.
The products offered by Modern Aminos are intended strictly for laboratory research purposes only and are sold exclusively to qualified professionals, institutions, and entities. These products are not for human consumption, veterinary use, or any other application involving living organisms, including but not limited to diagnostic, therapeutic, or recreational purposes.
By purchasing this product, you confirm that:
Modern Aminos does not claim that this product is approved by the U.S. Food and Drug Administration (FDA) for any purpose. The statements regarding this product have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
The buyer assumes full responsibility for ensuring the safe handling, storage, and use of this product. Modern Aminos is not liable for any damages, direct or indirect, resulting from improper handling, storage, or unauthorized use of this product. Furthermore, Modern Aminos reserves the right to refuse sales to any individual or entity suspected of misusing its products.
If you have questions about the safe and lawful use of this product, consult a qualified professional with expertise in laboratory research. By proceeding with this purchase, you agree to these terms and conditions.
